UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 816.1	$ 1,068.2
Short-term investments	100.0	100.0
Accounts receivable, net	413.8	416.9
Inventories	739.9	710.1
Assets held for sale	0.0	4.4
Other current assets	181.0	172.2
Total current assets	2,250.8	2,471.8
Property, plant and equipment, net	403.8	406.1
Goodwill	384.3	339.5
Intangible assets, net	227.5	211.8
Other long-term assets	284.3	220.8
Total assets	3,550.7	3,650.0
Current liabilities:
Current portion of long-term debt	11.0	112.4
Accounts payable	161.2	147.4
Customer advances	214.7	197.5
Other current liabilities	493.6	481.2
Total current liabilities	880.5	938.5
Long-term debt	1,205.4	1,221.8
Other long-term liabilities	426.7	404.9
Commitments and contingencies (Note 14)
Redeemable noncontrolling interest	6.8	0.2
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,046,105 and 174,905,035 shares issued and 149,291,702 and 150,753,687 shares outstanding at March 31, 2022 and December 31, 2021, respectively	1.7	1.7
Treasury stock, at cost, 25,754,403 and 24,151,348 shares at March 31, 2022 and December 31, 2021, respectively	(925.9)	(820.3)
Accumulated other comprehensive loss, net of tax	(17.1)	(8.2)
Other shareholders' equity	1,958.3	1,897.3
Total shareholders' equity attributable to Bruker Corporation	1,017.0	1,070.5
Noncontrolling interest in consolidated subsidiaries	14.3	14.1
Total shareholders' equity	1,031.3	1,084.6
Total liabilities, redeemable noncontrolling interest and shareholders' equity	$ 3,550.7	$ 3,650.0